Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 4/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539416 | 0.98 | HRH3 (0.47) | HRH3KCNH2MGLLSLC6A4HTT | |
| SCHEMBL3534510 | 0.91 | HRH3 (0.51) | HRH3KCNH2MGLLSLC6A4EGLN1 | |
| SCHEMBL3543369 | 0.89 | HRH3 (0.49) | HRH3KCNH2MGLLSLC6A4HTT | |
| SCHEMBL3535868 | 0.88 | HPGD (0.52) | HRH3KCNH2HTTHPGDL3MBTL1 | |
| SCHEMBL3539404 | 0.88 | HRH3 (0.49) | HRH3KCNH2MGLLSLC6A4HTT | |
| SCHEMBL27739834 | 0.88 | HRH3 (0.49) | HRH3KCNH2MGLLSLC6A4HTT | |
| SCHEMBL3538084 | 0.87 | HRH3 (0.50) | HRH3KCNH2MGLLHPGDALDH1A1 | |
| SCHEMBL3542678 | 0.86 | L3MBTL1 (0.54) | HRH3KCNH2HTTHPGDL3MBTL1 | |
| SCHEMBL3541059 | 0.86 | HTT (0.54) | HRH3KCNH2MGLLHTTHPGD | |
| SCHEMBL3537316 | 0.86 | HRH3 (0.43) | HRH3HPGDEGLN1L3MBTL1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601711-B2 | Such as [5-(4-cyclopentyl-piperazine-1-carbonyl)-1H-indol-2-yl]-morpholin-4-yl-methanone; histamine H3-antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-10-13 | — | — | US | claimed |
| US-7723325-B2 | 5-amido-indole-2-carboxamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090264418-A1 | 5-AMIDO-INDOLE-2-CARBOXAMIDE DERIVATIVES | NETTEKOVEN MATTHIAS | 2009-10-22 | — | — | US | disclosed |
| US-7601711-B2 | Such as [5-(4-cyclopentyl-piperazine-1-carbonyl)-1H-indol-2-yl]-morpholin-4-yl-methanone; histamine H3-antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2010487-A1 | 5-AMIDO-2-CARBOXAMIDE INDOLES | F. Hoffmann-Roche AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007115938-A1 | 5-AMIDO-2-CARBOXAMIDE INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| US-20070244125-A1 | 5-amido-indole-2-carboxamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264418-A1 | 5-AMIDO-INDOLE-2-CARBOXAMIDE DERIVATIVES | HRH4, HRH3, CNR2 | HRH3 2/4885KCNH2 684/4885MGLL 3528/4885 |
| US-20070244125-A1 | 5-amido-indole-2-carboxamide derivatives | HRH4, HRH3, CNR2 | HRH3 2/4885KCNH2 684/4885MGLL 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.